glp-1 and sglt2 help correct blood sugar,also reduce kidney disease which reduces heart disease ,with significant weight loss which helps to reduce blood pressure and fatty liver disease

Marker improvements in treatment compared to few years ago specially w newest GLP1 and GLPand GPIand SGLT2.
I wish insurances approved in non diabetic pts. I see a good response in my patients with diet and exercise as well. Hopefully
Medicare will start paying in non diabetic pt but risk factors of obesity CAD and renal insufficiency

more affordable treatment options due to competition and generic medications entering the market, AI generated platforms to monitor and educate patients daily, more devices available to monitor multiple parameters of metabolic health, newer medications, other specialties getting involved in obesity management, universal coverage of obesity medications

most important for the patient is education with respect to risk and how they can lose 5% of total body weight and still reduce risk of use GLP-1 is very can in patients who have, concomitant diabetes and impaired glucose tolerance and obesity frequent follow-ups referral to nutritional therapy continue to use the new therapies of monitoring such as continuous glucose monitoring to see postprandial hyperglycemic excursions her behavior

Yes many AI involved or implemented programs in addition to digital therapeutics will immensely affect our medical practice. Already implemented in some area, but for multifactorial faceted condition such as obesity and CV diseases will very much benefit from these technology.

we try to use GLP-1 in all obese patients but are frustrated by insurance copays. There is in my opinion a correlation with weight sugar and cardiovascular complications that can be overcome to a great degree with weight loss. Patients like the way they look and this translates to better care with themselves and their health. We try to get coverage and use cgm if patients can interact with options to control if insulin on board .

GLP1 agonists and life style modifications; Looking forward to better options like Cagrisema; Retatrutide and Maritide which will bring more robust and long lasting effects on weight loss

medditrean diet,exeercise,and approriate weight loss, medication,and stopping insulin resistance early in disease will stop cardivascular disease

I proactively offer GLP-1 agonists, but am frustrated by insurance roadblocks

More medications (especially the GLPS and SGLT2) are showing reduction in risk of cardiovascular mortality as well as exacerbation and hospitalization from Heart Failure. There continues to be introduction of smartphone applications that can assist in these areas not to mention worn devices like apple watches and CGMs

I see the increased use of sglt’s and glp’s in more and more patients even those with out diabetes,

I see mostly patients with diabetes as a general endocrinologist, and many of those are overweight and/obese. I aggressively go after weight loss in each patient, as this often given lower term success in diabetes treatment. I screen for CV disease and prescribe anti-hyperglycemics that have CV benefit/prevention of CAD. Metformin might even had CV benefit but not enough powered studies and TZDs have benefit if there is no heart failure. It is not just SGLT2/GLP-1s but I use those extensively as I imagine most here do.

About 80 % of pts with CVD are obese so it is of paramount importance to address obesity one of the most underprescribed modailty is the bariatric surgery yes there are GLP-1 agonist out there but when pt has to lose 100 pounds or so to come in the non obese range BS is the way go it is a life and risk factors changing phenomenon for them but challenge is to convince the pts to have it and BS is being underutiized in the smoke screen of the GLP-1 agonist !! BS is more sophisticated and safer than ever before ! Apart from that weight loss regimen revolves around the GLP-1 agonist in one form of the other with the availability of the compounded ones thanks to the national shortage of the branded ones it has become affordable for the self pay all kinds of CV , Metabolic and Renal benefits are there with them and they are getting broader FDA indications how ever diet and exercise part is being ignored and there is a one stop shop and panacea perspective of these agents ! weight loss is a life long struggle no matter what modaility is being utlized and that is the challenging part of it ! There are tons of apps available for the weight loss but the will and plan to follow one modality or the other comes from the continued health care provider encouragement and monitoring which is the cornerstone of this paradigm and can not be ignored !!!

Behavioral Health Interventions: Incorporating cognitive-behavioral therapy (CBT) and motivational interviewing can help address underlying psychological factors contributing to obesity and cardiovascular issues.

Community-Based Programs: Collaborating with local organizations to create accessible lifestyle modification programs can enhance support systems and increase patient participation.

Telehealth Services: Offering remote consultations and continuous monitoring can improve access to care and allow for timely interventions.

Integration of Technology
Wearable Devices: These can track physical activity, heart rate, and other vital signs, providing real-time feedback and encouraging patients to stay engaged in their health.

Mobile Health Apps: Apps for tracking diet, exercise, and medication adherence can empower patients to take control of their health and facilitate communication with healthcare providers.

Data Analytics: Utilizing big data and machine learning can help identify at-risk patients and predict outcomes, allowing for proactive management.

Telemonitoring: Remote monitoring of patients’ health metrics can lead to early detection of potential complications, improving management of both obesity and cardiovascular conditions.

Virtual Support Groups: Online communities can provide social support and shared experiences, helping to maintain motivation and adherence to treatment plans.

Overall, the integration of technology and innovative strategies holds great promise for enhancing patient outcomes in obesity and cardiovascular disease management.

I focus on lifestyle changes, discuss this at length during their physical appointments. I feel it works much better when they are younger. Emphasize regular exercises, weight loss, and prescribe GLP1s to assist their goals.
There are so many apps to track calories, CGMs to track glucose in real time..

today overweight and obesity make up to 70% of our cause;htn,diabets,dyslipidemia,sleep apnea,depression;pointing too cardiovasular disease

the introduction of new OTC CGM's from De\xcom and Abbott can hopefully raise awareness of the healthy diet choices in many patients with pre Dm OR NONINSULIN t2dm THEREFORE MAKING AN IMPACT ON CV MORBIDITY IN THE FUTURE.

Definite use of FITNESS APPS by patients like MY FITNESS PAL, getting all doctors - primary care and specialists on board with trying to help patients suffering from Obesity

I believe the future of obesity will encompass AI driven analysis of patients’ diets and exercise patterns to find the specific culprits unique to the patients which are driving these problems. I do not think a multi-disciplinary or even a polypeptide approach will be necessary for most people if the “treatment” is both natural and attainable and result-driven.

lifestyle changes, cardiac centric rehabilitation and exercise; medications which result in weight reduction and and MACE reduction: GLP-1 and GIP agonists. Many digital applications which connect the care team with the patients to follow trends. Population medical care to reduce MACE risk factors.

It’s important to stress diet and exercise, stress the cardio renal connection, use apps for education and use newer meds such as glp1

The future of obesity and cardiovascular care may include:

Precision nutrition
Personalized dietary recommendations based on an individual's phenotype, genotype, and other molecular factors.

Weight loss treatments
Evidence-based treatments that can lower the risk of cardiovascular events and other weight-related outcomes.

Cardiologist involvement
Cardiologists can address obesity and overweight to improve cardiovascular health.

Anti-inflammatory treatments
These treatments may reduce the burden of CVD, but their broad utility has been limited by lack of efficacy and off-target effects.

Bariatric surgery
This treatment can induce greater weight loss than other options and is associated with numerous health benefits.

Newer medications
Medications like semaglutide and tirzepatide produce robust weight loss efficacy that is approaching that of bariatric surgery.

Clinic design
Clinics should be designed for people with obesity, with durable chairs and tables, bathrooms, examination couches, gowns, weighing scales, and sphygmomanometer cuffs suited for a wide range of BMI categories.

Obesity is a major risk factor for cardiovascular disease. It contributes to the development of insulin resistance, endothelial dysfunction,

Use of glp-1 ra, or tirzepatide is important to improve parameters, reduce cardiovascular risks, bariatric surgery is an option too, very important lifestyle modifications, exercise.

My hope is that population nutritional education and information will be the first step in turning the tide. Without this we will continue to see this increase even with new medications.

Earlier use of GLP and GLP/GIP agents. Using a lot more CGMs for patients who have diabetes as a comorbidity. Remote patient monitoring using BP machines, having their weight monitored as well. RPM is sometimes hit or miss though - frequent visits are probably more reliable, but you need more providers. Linking up with nutritionists would be very helpful also

In a rural area, there are limited options. It would be wonderful if patients were able to access virtual visits with dieticians/nutritionists and fitness/exercise specialists. Additional, affordable apps with the ability to share data with the physician would be welcomed as well.

Digital therapeutic and AI integrated
approach would be the next. The future approach will encompass more dynamic and all rounded inclusive approach where it addressess all aspects of weight related problems

Supervise a multidisclinary weight managment program using a VLCD, LCD or meds. As effective as bariatric surgery with weight loss. Disappointed with mass remote monitoring. Frequent contact is important.

Innovative Strategies for Obesity and Cardiovascular Disease Management
Personalized Medical Nutrition Therapy

Tailored Dietary Plans: Based on metabolic profiles, genetic markers, and individual risk factors, we can create personalized nutrition plans that target both weight loss and cardiovascular health.
Anti-Obesity Medications (AOMs): In addition to lifestyle interventions, newer AOMs, such as GLP-1 receptor agonists (e.g., semaglutide), have been highly effective in reducing weight and improving cardiovascular outcomes by improving blood glucose control, lowering blood pressure, and reducing systemic inflammation.
Comprehensive Cardiometabolic Risk Assessment

Advanced Lipid Testing: Beyond traditional lipid panels, using more detailed analyses like LDL particle number and apolipoproteins to identify cardiovascular risks not evident in standard testing.
Body Composition Analysis: Regularly monitoring visceral fat and muscle mass helps identify improvements in metabolic health beyond simple weight changes.
Multidisciplinary Care Models

Integrated Teams: Collaborating with cardiologists, endocrinologists, dietitians, and exercise specialists allows for a holistic management plan that addresses both obesity and CVD simultaneously.
Behavioral Health Integration: Including mental health support to address emotional eating, motivation, and stress, which can contribute to both obesity and cardiovascular risks.
Role of Technology in Patient Management
Digital Health Platforms and Apps

Remote Monitoring: Use of apps that track physical activity, diet, weight, and vital signs (like heart rate and blood pressure) allows for real-time adjustments to treatment plans. This can improve adherence and early detection of changes in a patient’s condition.
Personalized Feedback: Apps using AI can provide tailored health tips based on patient inputs, creating more dynamic and responsive care models.
Wearable Technology

Continuous Glucose Monitors (CGMs): For patients with obesity and type 2 diabetes or prediabetes, CGMs provide real-time data on glucose fluctuations, helping guide dietary and medication adjustments.
Wearables for Heart Monitoring: Devices like smartwatches can monitor heart rate variability, blood pressure, and detect arrhythmias, giving patients and providers timely insights into cardiovascular status.
Telemedicine and Virtual Care

Frequent Follow-ups: Virtual visits make it easier for patients to receive regular care and coaching, especially for those with mobility issues due to obesity or those living in remote areas. This reduces barriers to consistent care and enhances engagement.
Remote Cardiometabolic Monitoring: Virtual tools can monitor blood pressure, weight, and even perform remote electrocardiograms (EKGs) for those with cardiovascular disease, allowing for continuous management without frequent in-person visits.
Artificial Intelligence (AI) and Predictive Analytics

Risk Prediction: AI-based algorithms can predict cardiovascular events and guide treatment intensity based on patient data, allowing for earlier intervention and more tailored treatment strategies.
Behavioral Insights: AI-driven platforms can analyze patient behaviors (e.g., adherence to exercise, diet) and provide recommendations or motivational prompts to increase engagement and success in weight loss or CVD risk reduction.
Future Directions
Digital Therapeutics: The rise of FDA-approved digital therapeutics for managing obesity and cardiovascular risk offers a new frontier in delivering evidence-based interventions via digital platforms.
Integration with Electronic Health Records (EHRs): Seamless integration of data from wearables, apps, and remote monitoring devices into EHRs will give clinicians a more comprehensive view of a patient’s health status, allowing for more informed decision-making.